Hyperion Biosystems
Founded in 2013 as an MIT spinout, the company develops diagnostic hardware and software that combine computer vision, physics-based algorithms and low-cost imaging to improve sensitivity and specificity of rapid, point-of-care and at-home assays. Key activities include development of connected diagnostic readers, time-gated luminescence imaging methods and materials, multiplex detection approaches for circulating and cell-free DNA, and algorithmic image-analysis deployed with commercial assay partners. The company has received NIH RADx awards and participates in government-funded diagnostic development programs.
Industries
Nr. of Employees
small (1-50)
Hyperion Biosystems
Watertown, Massachusetts, United States, North America
Products
Low-cost connected diagnostic reader for rapid assays
A reader platform intended to be used with rapid diagnostic assays that combines low-cost imaging hardware with physics-based and AI-enhanced image analysis to improve assay performance.
Multiplex detection method for circulating and cell-free DNA (in development)
A developing diagnostics capability focused on enhanced multiplex detection of circulating tumor DNA and cell-free DNA for diverse clinical use cases.
Helios
A new diagnostics capability focused on enhanced detection of circulating tumor and cell-free DNA across a variety of use cases.
Halo
A low cost, fully connected reader system for rapid diagnostic assays that simultaneously boosts sensitivity and specificity by leveraging a suite of physics-based, AI-enhanced algorithms.
Low-cost connected diagnostic reader for rapid assays
A reader platform intended to be used with rapid diagnostic assays that combines low-cost imaging hardware with physics-based and AI-enhanced image analysis to improve assay performance.
Multiplex detection method for circulating and cell-free DNA (in development)
A developing diagnostics capability focused on enhanced multiplex detection of circulating tumor DNA and cell-free DNA for diverse clinical use cases.
Helios
A new diagnostics capability focused on enhanced detection of circulating tumor and cell-free DNA across a variety of use cases.
Halo
A low cost, fully connected reader system for rapid diagnostic assays that simultaneously boosts sensitivity and specificity by leveraging a suite of physics-based, AI-enhanced algorithms.
Services
Development and integration of computer-vision and algorithmic solutions to improve assay sensitivity and specificity for partners in point-of-care and at-home testing.
Design and deployment support for low-cost, fully connected reader systems for rapid assays including hardware and software integration.
Development and integration of computer-vision and algorithmic solutions to improve assay sensitivity and specificity for partners in point-of-care and at-home testing.
Design and deployment support for low-cost, fully connected reader systems for rapid assays including hardware and software integration.
Expertise Areas
- Digital diagnostics
- Image-based diagnostic analytics
- Point-of-care and at-home testing
- Time-gated luminescence assays
Key Technologies
- Computer vision for diagnostic imaging
- Physics-based signal-processing algorithms
- AI-enhanced image analysis
- Time-gated luminescence imaging
News & Updates
Published paper demonstrating smartphone-based luminescence imaging as a promising tool for time-gated measurements.
Announcement of a licensing agreement to commercialize an on-dose authentication (anti-counterfeiting) technology for solid oral dosage pharmaceutical and nutraceutical products.
Secured NIH RADx awards to support development and commercialization of digitally connected at-home diagnostic readers and sensitivity-enhancement of rapid antigen tests.
Announcement of the successful closing of an $8M Series B financing round to accelerate development of a connected reader platform.
Published paper demonstrating smartphone-based luminescence imaging as a promising tool for time-gated measurements.
Announcement of a licensing agreement to commercialize an on-dose authentication (anti-counterfeiting) technology for solid oral dosage pharmaceutical and nutraceutical products.
Secured NIH RADx awards to support development and commercialization of digitally connected at-home diagnostic readers and sensitivity-enhancement of rapid antigen tests.
Announcement of the successful closing of an $8M Series B financing round to accelerate development of a connected reader platform.